Vera Therapeutics (VERA) Interest Expenses (2020 - 2026)

Vera Therapeutics (VERA) has 7 years of Interest Expenses data on file, last reported at $169.5 million in Q1 2026.

• Quarterly Interest Expenses rose 1354.32% year-over-year to $169.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $169.5 million (up 401.56% YoY) and the FY2025 annual result came in at $260.7 million, up 51.01% from the prior year.
• Interest Expenses climbed to $169.5 million in Q1 2026, from $56.1 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $169.5 million in Q1 2026 to a low of $559000.0 in Q4 2022.
• A 5-year average of $19.3 million and a median of $8.0 million in 2024 frame the typical range for Interest Expenses.
• Annual changes were most pronounced in 2024 — Interest Expenses plunged 86.13% — and 2025, when it jumped 2900.11%.
• Tracing VERA's Interest Expenses over 5 years: stood at $559000.0 in 2022, then soared by 2313.77% to $13.5 million in 2023, then sank by 86.13% to $1.9 million in 2024, then jumped by 2900.11% to $56.1 million in 2025, then jumped by 201.92% to $169.5 million in 2026.
• The last three Interest Expenses figures came in at $169.5 million (Q1 2026), $56.1 million (Q4 2025), and $3.2 million (Q3 2025), per Business Quant data.